Christine Giap

Title: Christine Giap: Innovator in Pharmacologic Inhibition of Myc Function

Introduction

Christine Giap is a prominent inventor based in Pittsburgh, PA (US). She has made significant contributions to the field of pharmacology, particularly in the context of cancer research. Her innovative work focuses on the c-Myc oncoprotein, which plays a crucial role in human cancers.

Latest Patents

Christine Giap holds a patent for her work titled "Pharmacologic inhibition of Myc function." This patent addresses the c-Myc oncoprotein, a helix-loop-helix-leucine zipper (HLH-ZIP) transcription factor that is often deregulated in various human cancers. Through a high throughput yeast-based assay, she identified seven low molecular weight substances that inhibit the association between c-Myc and Max, another HLH-ZIP protein. These compounds not only prevented this interaction in vitro but also inhibited the growth of c-Myc-expressing fibroblasts. Notably, short-term exposure to these compounds significantly reduced the tumorigenicity of c-Myc overexpressing fibroblasts in vivo. This research highlights the potential of yeast-based assays in identifying inhibitors of protein-protein interactions that can function effectively in mammalian cells.

Career Highlights

Christine Giap is affiliated with the University of Pittsburgh, where she continues her research and innovation in pharmacology. Her work has garnered attention for its implications in cancer treatment and the understanding of protein interactions.

Collaborations

Christine has collaborated with notable colleagues, including Edward V Prochownik and John S Lazo. Their combined expertise has contributed to advancing research in the field of cancer pharmacology.

Conclusion

Christine Giap's innovative research and patent on the pharmacologic inhibition of Myc function represent a significant advancement in cancer treatment strategies. Her work exemplifies the importance of collaboration and innovation in scientific research.